Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: Posthoc analysis from V.I.S.I.O.N. study

British Journal of Ophthalmology

Volumn 98, Issue 11, 2014, Pages 1543-1546

  Boyer, David S ^a   Goldbaum, Mauro ^b   Leys, Anita M ^c   Starita, Carla ^d  

^a RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; PEGAPTANIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; APTAMER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; ARTICLE; CONTROLLED STUDY; GLAUCOMA; GOLDMANN APPLANATION TONOMETER; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYDRIASIS; PRESSURE MEASUREMENT; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA HEMORRHAGE; SCAR FORMATION; SUBRETINAL NEOVASCULARIZATION; TONOMETRY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; WET MACULAR DEGENERATION;

ADULT; ANGIOGENESIS INHIBITORS; APTAMERS, NUCLEOTIDE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84911991755     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304075     Document Type: Article

References (18)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
3. D'Amico DJ, Masonson HN, Patel M, et al . Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001.e1006.
4. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-11.
5. Bakri SJ, McCannel CA, Edwards AO, et al. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-8.
6. Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-14.
7. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011;31:1028-35.
8. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21:241-7.
9. Regeneron. EYLEA™ (aflibercept) injection for intravitreal injection: prescribing information. 2011. http://www.regeneron.com/Eylea/eylea-fpi.pdf (accessed 11 May 2012).
10. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 2010;4:28-9.
11. Gonzales CR. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005;25:815-27.
12. Colton T, Ederer F. The distribution of intraocular pressures in the general population. Surv Ophthalmol 1980;25:123-9.
13. Wehrli SJ, Tawse K, Levin MH, et al. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 2012;32:1295-301.
14. Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119:321-6.
15. Skalicky SE, Ho I, Agar A, et al. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 2012;43:328-34.
16. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 2010;19:437-41.
17. Friberg TR, Tolentino M, Weber P, et al. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 2010;94:1611-17.
18. European Medicines Agency. Macugen: procedural steps taken and scientific information after the authorisation. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Procedural-steps-taken-and-scientific-information-after-authorisation/human/000620/WC500026220.pdf (accessed 11 Dec 2014).